Embed Size (px)
Citation preview
Delivering clinical research to make patients, and the NHS, better
Gynaecology SSG Sept 2015
Research
Jenny Forrest, Sub Specialty LeadWendy Cook, Research Delivery Manager
dd/mm/yyyy
Gynaecological Tumour Group National Perspective
Data from Portfolio ODP – Cut off 21/08/15
Gynaecological Tumour Group National Perspective
Data from Portfolio ODP – Cut off 21/08/15
Network
2014/2015 2015/2016
Commercial Non-Commercial Total Rank Commercial Non-
Commercial Total Rank
East Midlands 12 65 77 9 1 9 10 13
Eastern 35 312 347 1 3 125 128 1
Greater Manchester 17 105 122 4 3 27 30 4
Kent, Surrey and Sussex 18 39 57 12 0 12 12 11
North East and North Cumbria 12 55 67 11 0 17 17 8
North Thames 22 104 126 3 1 20 21 5
North West Coast 10 64 74 10 1 10 11 12
North West London 12 107 119 5 3 31 34 2
South London 50 142 192 2 3 31 34 2
South West Peninsula 12 94 106 6 2 17 19 7
Thames Valley and South Midlands 0 19 19 15 0 4 4 15
Wessex 15 8 23 14 5 0 5 14
West Midlands 24 59 83 8 4 11 15 10
West of England 4 51 55 13 1 15 16 9
Yorkshire and Humber 24 79 103 7 2 18 20 6
Gynaecological Tumour Group Open StudiesSouth West Peninsula
Data from Portfolio ODP – Cut off 21/08/15
Study Name UKCRN ID Study Type Study
DesignOpen to New
Sites?Total
Recruitment
DNA Methylation Study 1449 Non-Commercial
Observational Yes (LC) 211
ICON8 Trials Programme 9812 Non-Commercial
Interventional Yes 80
INTERLACE 11775 Non-Commercial
Interventional Yes 8
Gynaecological Tumour Group South West Peninsula Sites
Data from Portfolio ODP – Cut off 21/08/15
Trust
2014/2015 2015/2016
Commercial Non-Commercial Total Commercial Non-
Commercial Total
Northern Devon Healthcare NHS Trust 0 5 5 0 0 0
Plymouth Hospitals NHS Trust 0 42 42 0 1 1
Royal Cornwall Hospitals NHS Trust 3 8 11 0 0 0
Royal Devon and Exeter NHS Foundation Trust 2 9 11 0 0 0
South Devon Healthcare NHS Foundation Trust 5 4 9 2 0 2
Taunton and Somerset NHS Foundation Trust 0 23 23 0 16 16
Yeovil District Hospital NHS Foundation Trust 2 3 5 0 0 0
Data from CRN SWP Activity Data from EDGE July 2015
Acronym UKCRN ID Study Type Trust Investigator Name End Date Target Recruitment 2015/2016
Recruitment RTT
CX.5 (SHAPE):Early Stage 1A2 and 1B1
17481 Non-Commercial
Royal Cornwall Hospitals NHS Trust
Galaal, Ms Khadra 13-Jul-22 28 0 0 -1
DESKTOP III 11498 Non-Commercial
Royal Cornwall Hospitals NHS Trust
Galaal, Ms Khadra 31-Aug-18 2 0 0 -42
DNA Methylation Study
1449 Non-Commercial
Plymouth Hospitals NHS Trust
Hughes, Mr Geoff 31-Dec-17 20 104 1 439
DNA Methylation Study
1449 Non-Commercial
Royal Cornwall Hospitals NHS Trust
Lopes, Mr Alberto 31-Dec-17 30 23 0 -5
DNA Methylation Study
1449 Non-Commercial
Taunton and Somerset NHS Foundation Trust
Milliken, Mr David 01-Oct-15 15 66 16 342
GROINSS-V II 4971 Non-Commercial
Royal Cornwall Hospitals NHS Trust
Lopes, Mr Alberto 31-Jan-17 5 0 0 -79
ICON8: Weekly Chemotherapy in Ovarian Cancer
9812 Non-Commercial
Northern Devon Healthcare NHS Trust
Scatchard, Dr Kate 30-Nov-14 25 17 0 -54
ICON8: Weekly Chemotherapy in Ovarian Cancer
9812 Non-Commercial
Royal Cornwall Hospitals NHS Trust
Bailey, Dr Nigel 30-Nov-14 8 11 0 120
ICON8: Weekly Chemotherapy in Ovarian Cancer
9812 Non-Commercial
Royal Devon and Exeter NHS Foundation Trust
Scatchard, Dr Kate 30-Nov-14 12 27 0 54
7
Gynaecological Tumour Group South West Peninsula Open Studies
Acronym UKCRN ID Study Type Trust Investigator Name End Date Target Recruitment 2015/2016
Recruitment RTT
INTERLACE 11775 Non-Commercial
Northern Devon Healthcare NHS Trust
Forrest , Dr Jennifer 01-Jun-16 3 4 0 58
INTERLACE 11775 Non-Commercial
Royal Devon and Exeter NHS Foundation Trust
Forrest, Dr Jenny 01-Jun-16 9 4 0 -27
NiCCC Trial (BIBF1120) 15374 Non-
Commercial
Taunton and Somerset NHS Foundation Trust
Barlow, Dr Clare 15-Nov-19 4 0 0 -5
PETROC/OV21 7472 Non-Commercial
Plymouth Hospitals NHS Trust
Yiannakis, Dr DeINTERLACE 01-Jun-18 5 3 0 1
nnis
TRIOC 12591 Non-Commercial
Plymouth Hospitals NHS Trust
Yiannakis, Dr Dennis 01-Oct-14 5 0 0 -207
Gynaecological Tumour Group South West Peninsula Sites
Data from Portfolio ODP – Cut off 21/08/15
Gynaecological Tumour Group Open Studies
Data from Portfolio ODP – Cut off 21/08/15
East Midlands
Study Name Total Recruitment
DNA Methylation Study 34
ENGOT-EN2-DGCG-EORTC-55102 4
GROINSS-V II 41
ICON8 Trials Programme 67
INTERLACE 14
NCRN - 2597 AEZS-108 vs doxorubicin in 2nd line advanced endometrial ca
5
NCRN - 3244 - Masitinib + Gemcitabine VS Gemcitabine in Ovarian Cancer
1
PARAGON 3
TRIOC: TroVax® in Relapsed Ovarian Cancer 1
Eastern
Study Name Total Recruitment
BriTROC1 - Sample collection study in recurrent HGSOC 28
CORAL: Cancer of the OvaRy Abiraterone triaL 8
CTCR-OV04 221
CTCR-OV05 13
Diffusion weighted Imaging Study in Cancer of the Ovary (DISCOVAR) 47
DNA Methylation Study 77
GROINSS-V II 48
ICON8 Trials Programme 122
INTERLACE 1
METRO-BIBF 8
NCRN - 2746 / ARIEL 3 - Rucaparib in platinum-sensitive high-grade gynaecological cancer
1
PARAGON 8
PAZOFOS 3
Uterine LMS study 1
Gynaecological Tumour Group Open Studies
Data from Portfolio ODP – Cut off 21/08/15
Greater Manchester
Study Name Total Recruitment
BriTROC1 - Sample collection study in recurrent HGSOC 11
DNA Methylation Study 1
GROINSS-V II 26
ICON8 Trials Programme 107
INTERLACE 3
Metformin for endometrial cancer RCT 17
METRO-BIBF 7
MIRENA study 22
NCRN - 2746 / ARIEL 3 - Rucaparib in platinum-sensitive high-grade gynaecological cancer
4
NCRN - 3244 - Masitinib + Gemcitabine VS Gemcitabine in Ovarian Cancer
1
PARAGON 8
PAZOFOS 3
TRIOC: TroVax® in Relapsed Ovarian Cancer 2
Kent, Surrey and SussexStudy Name Total Recruitment
DNA Methylation Study 33
ENGOT-EN2-DGCG-EORTC-55102 1
EORTC Quality of Life Module for patients with vulva cancer
8
GROINSS-V II 12
ICON8 Trials Programme 79
METRO-BIBF 4
PARAGON 8
TRIOC: TroVax® in Relapsed Ovarian Cancer 5
Gynaecological Tumour Group Open Studies
Data from Portfolio ODP – Cut off 21/08/15
North East and North Cumbria
Study Name Total Recruitment
BriTROC1 - Sample collection study in recurrent HGSOC
1
Diffusion weighted Imaging Study in Cancer of the Ovary (DISCOVAR)
3
DNA Methylation Study 186
GROINSS-V II 7
ICON8 Trials Programme 72
INTERLACE 2
PARAGON 12
North Thames
Study Name Total Recruitment
BriTROC1 - Sample collection study in recurrent HGSOC 24
DEPICT 12
DNA Methylation Study 68
GROINSS-V II 30
ICON8 Trials Programme 130
INTERLACE 22
METRO-BIBF 11
NCRN - 2746 / ARIEL 3 - Rucaparib in platinum-sensitive high-grade gynaecological cancer
4
Uterine LMS study 1
Gynaecological Tumour Group Open Studies
Data from Portfolio ODP – Cut off 21/08/15
North West Coast
Study Name Total Recruitment
ICON8 Trials Programme 106
INTERLACE 2
MAPPING 25
METRO-BIBF 5
NCRN - 2597 AEZS-108 vs doxorubicin in 2nd line advanced endometrial ca
1
PARAGON 9
TRIOC: TroVax® in Relapsed Ovarian Cancer 6
North West London
Study Name Total Recruitment
BriTROC1 - Sample collection study in recurrent HGSOC 22
CANC - 3792 REFMAL 339: ME-344 with Topotecan in Solid Tumors 2
DEPICT 5
Diffusion weighted Imaging Study in Cancer of the Ovary (DISCOVAR) 17
ICON8 Trials Programme 70
MAPPING 39
NCRN - 2597 AEZS-108 vs doxorubicin in 2nd line advanced endometrial ca
8
NCRN - 2746 / ARIEL 3 - Rucaparib in platinum-sensitive high-grade gynaecological cancer
2
ProGem2 - Acelarin(NUC1031) plus Carboplatin for recurrent ovarian cancer
14
The role of obesity and diabetes in endometrial cancer 31
BriTROC1 - Sample collection study in recurrent HGSOC 22
Gynaecological Tumour Group Open Studies
Data from Portfolio ODP – Cut off 21/08/15
South LondonStudy Name Total Recruitment
ADC as a Prognostic Biomarker in Cervical Cancer 95
BriTROC1 - Sample collection study in recurrent HGSOC 2
CORAL: Cancer of the OvaRy Abiraterone triaL 14
DEPICT 3
Diffusion weighted Imaging Study in Cancer of the Ovary (DISCOVAR) 47
ICON8 Trials Programme 72
MAPPING 13
METRO-BIBF 15
NCRN - 2597 AEZS-108 vs doxorubicin in 2nd line advanced endometrial ca
8
NCRN - 2746 / ARIEL 3 - Rucaparib in platinum-sensitive high-grade gynaecological cancer
5
PARAGON 17
PAZOFOS 4
Uterine LMS study 1
Thames Valley and South Midlands
Study Name Total Recruitment
ICON8 Trials Programme 35
METRO-BIBF 4
PARAGON 2
TRIOC: TroVax® in Relapsed Ovarian Cancer
3
Gynaecological Tumour Group Open Studies
Data from Portfolio ODP – Cut off 21/08/15
Wessex
Study Name Total Recruitment
DNA Methylation Study 66
ICON8 Trials Programme 23
NCRN - 3244 - Masitinib + Gemcitabine VS Gemcitabine in Ovarian Cancer
3
West Midlands
Study Name Total Recruitment
BriTROC1 - Sample collection study in recurrent HGSOC 3
DNA Methylation Study 1
EPIVIN trial 14
GROINSS-V II 25
ICON8 Trials Programme 155
INTERLACE 4
MAPPING 5
NCRN - 2597 AEZS-108 vs doxorubicin in 2nd line advanced endometrial ca
5
NCRN - 3244 - Masitinib + Gemcitabine VS Gemcitabine in Ovarian Cancer
2
PARAGON 2
ROCkeTS 4
Gynaecological Tumour Group Open Studies
Data from Portfolio ODP – Cut off 21/08/15
West of England
Study Name Total Recruitment
BriTROC1 - Sample collection study in recurrent HGSOC 4
CORAL: Cancer of the OvaRy Abiraterone triaL 8
DNA Methylation Study 77
GROINSS-V II 1
ICON8 Trials Programme 80
METRO-BIBF 5
PARAGON 1
TRIOC: TroVax® in Relapsed Ovarian Cancer 3
Yorkshire and Humber
Study Name Total Recruitment
Actinomycin-D vs Methotrexate for treatment of low risk GTN 4
BriTROC1 - Sample collection study in recurrent HGSOC 11
DNA Methylation Study 111
ENGOT-EN2-DGCG-EORTC-55102 3
GROINSS-V II 27
ICON8 Trials Programme 68
INTERLACE 9
METRO-BIBF 2
NCRN - 2597 AEZS-108 vs doxorubicin in 2nd line advanced endometrial ca 2
NCRN - 2746 / ARIEL 3 - Rucaparib in platinum-sensitive high-grade gynaecological cancer
3
PARAGON 5
SHAPE - Simple Hysterectomy And Pelvic node dissection in Early cervix cancer
1
Division 1- Cancer - Contacts
• Duncan Wheatley, Clinical Specialty Lead [email protected] 01872 258312
• Jenny Forrest, Sub specialty lead [email protected] 01392 402106
• Wendy Cook, Research delivery manager
[email protected] 01392 406995
• Ann Courtman, Administrator [email protected]
01392 406966
16
